Dansk
Nederlands
English
Suomi
Français
Deutsch
Ελληνικά
Italiano
Norsk
Polski
Português
Español
Svenska
Retatrutide
Price range: € 47,95 through € 264,95
Don't forget the reconstitution water
Required for dissolving freeze-dried peptides.
All products are intended for laboratory research only and are not suitable for human or animal consumption. By purchasing, the buyer agrees to use these products in accordance with all applicable laws.
This substance has not been evaluated or approved by the European (EMA), American (FDA) or Dutch (MEB/IGJ) medicines authorities for any human or veterinary use. No medical, therapeutic, diagnostic or preventive use is claimed or implied.
Retatrutide is a synthetic, experimental peptide that has been developed as a multi-pathway agonist. It is currently being studied for its potential effects on receptor-mediated signaling, molecular dynamics, and endocrine functions in preclinical research models. By activating multiple target receptor subtypes, Retatrutide exhibits broad systemic effects that are being investigated for their relevance within endocrine and pathway-directed research.
Jastreboff A.M. et al., 2023
History
The development of Retatrutide builds on decades of research within peptide signaling science. Early studies with single-pathway agonists demonstrated their role in downstream signaling and receptor activity. Later studies extended this to dual-agonist models, eventually paving the way for Retatrutide, which uniquely combines three pathway targets.
This multi-agonist design represents a new direction within peptide research, aimed at studying broader receptor-mediated modulation in preclinical laboratory settings.
Coskun T. et al., 2022
Retatrutide Structure
CAS #: 2381089-83-2
Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4845.44 g/mol
PubChem ID: 474492335
Research findings
Retatrutide has been investigated in endocrine and systemic models, with studies describing its influence on receptor binding kinetics, downstream signaling cascades, lipid pathway dynamics, and integrated endocrine pathways. Research also points to involvement in multisystem signaling and pathway characterization within preclinical and laboratory settings.
Key Research Areas
Endocrine
• Receptor binding
• Signaling processes
• Signaling cascades
Pathways
• Target receptor subtypes
• Modulation
• Dynamics
Vascular
• Lipid pathways
• Hepatic signaling
• Biomarkers
Systemic
• Multi-pathway signaling
• Biological resilience
• Characterization
Together, these findings suggest a broad experimental potential for DP3-R within endocrine, vascular and systemic models. By activating multiple pathway targets, it provides a versatile research platform for studying downstream signaling cascades and integrated molecular responses within diverse biological systems.
Jastreboff A.M. et al., New England Journal of Medicine, 2023
References
Jastreboff A.M. et al. (2023). Triple-hormone receptor agonist retatrutide in obesity — a randomized, controlled trial. New England Journal of Medicine, 389(1), 11–24.
Coskun T. et al. (2022). Retatrutide: A triple-hormone receptor agonist for obesity and diabetes. Diabetes, 71(7), 1435–1449.
Our Process
Frequently asked questions
Each batch is independently tested by third-party laboratories using HPLC and mass spectrometry. You can view the Certificate of Analysis (COA) of your specific batch on our lab results page.
Orders placed before 15:00 will be shipped the same day from our EU warehouse. Delivery typically takes 1–3 business days, depending on your location within Europe.